Optimal treatment of premature ovarian failure after treatment for Hodgkin s lymphoma is often withheld
|
|
- Josephine Whitehead
- 5 years ago
- Views:
Transcription
1 Acta Obstetricia et Gynecologica. 2006; 85: ORIGINAL ARTICLE Optimal treatment of premature ovarian failure after treatment for Hodgkin s lymphoma is often withheld SYLVIA I. VERSCHUUREN 1, JISKA J. SCHAAP 1, MARS B. VAN T VEER 2, THEO STIJNEN 3, CURT W. BURGER 1 & ANCA C. ANSINK 1 1 Department of Gynecologic Oncology, University Medical Center Rotterdam, 3015 GD, 2 Department of Hematology, University Medical Center Rotterdam, 3075 EA, and 3 Department of Epidemiology & Biostatistics, University Medical Center Rotterdam, 3000 DR Rotterdam, The Netherlands Abstract Background. The purpose of this study is to determine: 1. the effect of treatment for Hodgkin s lymphoma on ovarian function, and 2. the interventions to relieve postmenopausal symptoms. Methods. Seventy-seven consecutive patients treated between 1989 and 2003 in the Rotterdam region for Hodgkin s lymphoma stages I and II were approached for this study. A questionnaire consisting of 45 questions was carried out to evaluate premature menopausal symptoms, hormonal replacement therapy and use of, menstrual cycle, and subsequent pregnancies. Results. After informed consent 67 patients were willing to participate in the study and 66 patients filled in a questionnaire. After antitumor treatment 13 patients developed treatment-related premature ovarian failure, 35 patients had a spontaneous cycle, and 18 patients could not be classified as they used hormonal. Women who developed treatment-related premature ovarian failure had a significantly higher mean age at the start of treatment for Hodgkin s lymphoma than women who remained premenopausal (p B/0.002). Only 6 of these 13 women (46%) received hormonal substitution. In all, 21 women conceived after antitumor treatment, and 28 children were born. All pregnancies were the result of spontaneous conception. Conclusions. The effect of antitumor treatment for Hodgkin s lymphoma on ovarian function is age dependent (odds ratio of 1.18 per year). There is a striking inconsistency regarding the management of ovarian protection before and during antitumor treatment. Premenopausal women who undergo therapy for Hodgkin s lymphoma should be offered hormonal substitution therapy after loss of ovarian function. Key words: Premature ovarian failure, Hodgkin s lymphoma, antitumor treatment, fertility, GnRH-a Abbreviations: HL: Hodgkin s lymphoma, POF: premature ovarian failure, GnRH-a: gonadotrophin-releasing hormone agonist, EORTC: European Organisation for Research and Treatment of Cancer, HRT: hormone replacement therapy The peak incidence of Hodgkin s lymphoma (HL) is in the third decade of life, making the disease the most common malignancy in the population aged between 15 and 24 years. As the introduction of aggressive antitumor treatment in young patients has brought long-term disease-free survival ( /90%) after HL, quality of life has become an important issue (1 3). For young women treated with multiple agent chemotherapy in their fertile age, preservation of fertility and future fertility is an important aspect of quality of life. The aim of this study was to investigate retrospectively the effect of treatment for HL on ovarian function, and the use of hormone replacement therapy (HRT) to control postmenopausal symptoms. Furthermore we investigated the potential impact of age at the start of treatment of HL. Methods We conducted a population-based study of all women in the Rotterdam region treated for HL Correspondence: A.C. Ansink, Erasmus MC, Daniel den Hoed Oncology Center, P.O. Box 5201, 3008 AE Rotterdam, The Netherlands. a.ansink@erasmusmc.nl (Received 25 October 2005; accepted 8 March 2006) ISSN print/issn online # 2006 Taylor & Francis DOI: /
2 998 S.I. Verschuuren et al. stage I and II from 1989 until Eligibility criteria were female patients with HL who were not treated with bone marrow transplantation, aged between 18 and 45, premenopausal at the time of primary treatment, and who had no history of other malignancies. The protocol was approved by the medical ethical board of the Erasmus Medical Center. The patients studied were treated within three European Organisation for Research and Treatment of Cancer (EORTC) trials (H7, H8, and H9). Treatment schedules were according to one of these three protocols (4). A validated questionnaire (5) consisting of 45 questions was sent to all eligible women preceded by information on the study and an informed consent form. Questions dealt with premature menopausal symptoms (such as amenorrhea, oligomenorrhea, hot flushes, sweating, dyspareunia, and depression), hormonal replacement and use of, menstrual cycle, subsequent pregnancies and their outcome, and health status of the children who were born after their mothers treatment for HL. The information obtained from the questionnaires was compared with data from the hospital records. We considered women as suffering from treatmentrelated premature ovarian failure (POF) if they did not resume their spontaneous menstrual cycle within five years after antitumor treatment. We mainly looked at after primary treatment, but we also collected data on after treatment for recurrent disease. A computerized database in SPSS 11.0 was created for the analysis of the data. The yearly odds ratio of treatment-related POF and age at the start of treatment of HL was estimated by using logistic regression. Results From 1989 until 2003, 122 women in the Rotterdam region were treated for HL stage I and II. Forty-five of these women were not eligible for our study. In Table I, the reasons for in- and exclusion are presented. Thus, 77 patients were eligible and they were approached for this study. Ten patients refused to participate. One patient signed a consent form, but did not submit the questionnaire. The median age of the remaining 66 patients was 27 years (range years) at the start of treatment for HL. Median follow-up was 10 years (range months). Primary antitumor treatment modalities and dosage of radiation are presented in Table II. Seven patients were treated for recurrent disease. Table I. In- and exclusion criteria for 122 women treated for Hodgkin s lymphoma in the Rotterdam region between 1989 and 2003 Included 77 Excluded 45 DOD 11 Age B/18 or /45 years 23 Bone marrow transplantation 4 Second primary malignancy 1 Follow-up time B/10 months 2 Emigration 2 Lost to follow-up 2 DOD, dead of disease Four patients received MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine) and three patients received MOPP (mechlorethamine, vincristine, procarbazine, prednisone). Menopausal status after primary treatment We divided our patient population into three subgroups. Women in group A developed treatmentrelated POF, women in group B remained premenopausal, and women in group C could not be classified. Group A consisted of 8 patients (12%). The median age of the 8 women who developed treatment-related POF was 37 years (range years). Group B consisted of 40 patients with a median age of 24 years (range 1842 years) who preserved a spontaneous cycle after antitumor treatment. Group C consisted of 18 patients. It was decided that we could not classify these patients as they used hormonal. None of these women became pregnant after antitumor treatment. The median age of these 18 patients was 28 years (range years). Women who developed treatment-related POF had a significantly higher average age at the time they started treatment for HL than women who remained premenopausal (p B/0.002). The yearly odds ratio (1.35) also showed this agedependent association. Menopausal status after secondary treatment Seven women were treated for recurrent disease. As a result of the second treatment, five women developed treatment-related POF. Three of these patients received a combination of chemotherapy and radiotherapy for their primary tumor and chemotherapy alone for the recurrent disease. Four patients were treated with radiotherapy for their primary tumor and with chemotherapy for the recurrence. Two of these patients developed treatment-related POF.
3 Table II. Primary antitumor treatment of 66 women treated for Hodgkin s lymphoma Treatment of ovarian failure after Hodgkin s lymphoma 999 Chemotherapy Involved field radiation Mantle field radiation Subtotal nodal radiation, supraand infradiaphragmatic Agents Cycles 0 Gy 20 Gy 30 Gy 36 Gy 38 Gy 40 Gy 36 Gy 40 Gy 40 Gy/36 Gy EBVP MOPP/ABV MOPP/ABV MOPP/ABV 3 1 BEACOPP ABVD EBVP: epirubicin, bleomycin, vinblastine, prednisone; MOPP/ABV: mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine; BEACOPP: cyclophosphamide, doxorubicin, vincristine, bleomycin, etoposide, procarbazine, prednisone; ABVD: doxorubicin, bleomycin, vinblastine, dacarbazine After secondary treatment, group A consisted of 13 patients (20%) with a median age of 34 years (range 1944 years), and group B consisted of 35 patients with a median age of 24 years (range 1842 years). At the start of treatment for HL, the mean age of the women in group A was significantly higher than the age of the women in group B (p B/0.002), with an odds ratio of 1.18 per year (Figure 1). Pregnancies After primary antitumor treatment, 19 patients conceived. Median follow-up after antitumor treatment was 5 years (range 313 years). Two patients conceived after treatment for recurrent disease. The two children were born within three and six years after the last treatment. All pregnancies were the result of spontaneous conception (Figure 2). Three women had an ectopic pregnancy. Subsequently, one of these three women gave birth to a healthy child. Predicted probability to develop premature ovarian failure Age at the start of treatment for Hodgkin's lymphoma Figure 1. The relation between age at the start of treatment for Hodgkin s lymphoma and the predicted probability of developing premature ovarian failure (POF) for 48 patients. One woman had two miscarriages, but gave subsequently birth to a healthy child. In total, 27 healthy children and one child with Down syndrome were born. One patient was still pregnant at the time of the current analysis. Hormone replacement therapy Hormonal treatment for substitution of loss of ovarian function was prescribed to nine women (Figure 3). HRT according to national guidelines was prescribed to six patients (46%). Three women received oral as HRT, and four patients received no HRT for obscure reasons. All patients of group C used hormonal. Discussion Ovarian failure is a well known consequence of exposing female gonads to antitumor treatment for HL (6 9). Long-term disease-free survival after HL in young patients has improved dramatically ( /90%), therefore quality of life and thus preservation of fertility have become important issues. In accordance with the literature (10,11), treatment for HL has a negative effect on ovarian function. It was demonstrated in our study that 13 (20%) women younger than 45 years developed treatment-related POF. In the current study, women who developed treatment-related POF had a significantly higher average age than women who remained premenopausal. This is compatible with the literature (12,13). The median age in group C was higher than in group B and lower than in group A. Among the patients in group C, some patients probably developed treatment-related POF. However, due to continuous hormonal contraceptive use, this could not be established. Treatment with a gonadotrophin-releasing hormone agonist (GnRH-a) starting two weeks before
4 1000 S.I. Verschuuren et al. 77 eligible patients treatment for HL After primary treatment 10 no consent form 1 no questionnaire submitted 40 premenopausal 8 postmenopausal 18 unclassified 19 women pregnant 21 women not pregnant 25 children 1 still pregnant 2 ectopic 1 abortion 2 miscarriages 1 child with Down syndrome 24 healthy children After primary and secondary treatment 21 women pregnant 35 premenopausal 13 postmenopausal 18 unclassified 14 women not pregnant 28 children 1 still pregnant 3 ectopic 1 abortion 2 miscarriages 1 child with Down syndrome 27 healthy children Figure 2. Menopausal status and pregnancies of 66 women after primary and secondary* treatment for Hodgkin s lymphoma. *Seven women received secondary treatment for recurrence. chemotherapy appears to be a promising approach to prevent ovarian failure induced by antitumor treatment. However, only one randomized study on this issue has been conducted (14). Pereyra Pacheco et al. (15) have shown that GnRH-a treatment before and during antitumor treatment enhances ovarian function and preserves fertility. Blumenfeld and Eckman (16) have reported on the largest group of females exposed to both cytotoxic drugs and GnRH-a thus far. The rate of POF was 7% in the GnRH-a/chemotherapy group versus 54% in the chemotherapy-alone group. Because of these promising results, it is striking that, to the best of our knowledge, no large multicenter studies have been conducted, although it has been suggested in reviews several times (13). In order to assess the effectiveness of GnRH-a on the protection of ovarian damage properly, such a large multicenter study should be initiated. In recent years, several different techniques to preserve ovarian tissue have been developed (17,18). Several cases of restoration of ovarian function after autotransplantation of cryopreserved ovarian tissue have now been published (1922), and recently three pregnancies due to cryopreserved and returned ovarian tissue were claimed (20 22). However, success rates of this technique are obscure, as it is not known how many failures preceded these three apparently successful cases. Furthermore, two concerns regarding cryopreservation of ovarian tissue should be borne in mind. First, for cryopreservation a laparoscopy is needed. Although the complication rate of this operation is low, it is not negligible. And in addition, laparoscopy implies that the patient will have to submit herself to another procedure within the short time-span that will be filled with numerous diagnostic interventions and counseling procedures before antitumor treatment can start. Secondly, returning cryopreserved ovarian tissue may result in transferring cancer cells back into the patient during the autograft procedure (17). Recent research with mice on this issue was reassuring (23). However, the potential risk
5 Treatment of ovarian failure after Hodgkin s lymphoma eligible patients treatment for HL After primary treatment 10 no consent form 1 no questionnaire submitted 40 premenopausal 8 postmenopausal 18 unclassified 9 oral 2 continuous 29 no hormonal 2 oral 2 HST 4 no hormonal 15 oral 3 continuous After primary and secondary treatment 35 premenopausal 13 postmenopausal 18 unclassified 7 oral 2 continuous 26 no hormonal 3 oral 6 HST 4 no hormonal 15 oral 3 continuous Figure 3. Menopausal status and hormonal treatment of 66 women after primary and secondary* treatment for Hodgkin s lymphoma. *Seven women received secondary treatment for recurrence. of transferring cancer cells into a cured cancer patient cannot be ruled out completely. In the present study, we did not incorporate questions on cryopreservation as the technique was not available during the entire study period ( ). Despite antitumor treatment, 21 women gave birth to 27 healthy children. Three women had an ectopic pregnancy. In the literature, we could not identify any data on ectopic pregnancy risk after antitumor treatment. It is remarkable that several postmenopausal women in our study were not offered HRT. Some were prescribed hormonal instead of HRT, which is not in line with national and international guidelines, as oral do not contain the appropriate dosage or the appropriate drugs to alleviate postmenopausal symptoms. Furthermore, women with treatment-related POF who use hormonal instead of hormone substitution will have postmenopausal symptoms during the pill-free period (usually one week per month). This will of course result in a reduced quality of life. It was obscure to us why some attending physicians choose to prescribe oral to women with treatment-related POF. Female survivors of HL have a strongly elevated risk of breast cancer when they have been treated with radiation in the area of the breast (24). On the other hand, women who develop treatment-related POF have a reduced risk of breast cancer. Theoretically, HRT could neutralize this reduced risk. Postmenopausal women who use HRT may eventually develop the same risk of breast cancer as women who remained premenopausal after treatment for HL. However, there is no evidence that women who develop treatment-related POF have an increased risk of breast cancer when compared with women who remain premenopausal after this treatment. With this issue in mind, if and how to substitute women who develop treatment-related POF is a matter of debate and possibly of individualization, weighing risk versus quality of life (12,25,26). This applies in particular to women who received irradiation on the breast (24). It is obvious that expert care for iatrogenic postmenopausal symptoms was withheld from several women who underwent intensive antitumor treatment. In group C, all patients used hormonal in order to prevent pregnancy. However, several of these women expressed symptoms compatible with POF in their questionnaire. It is therefore likely that these patients suffered from treatmentrelated POF and inadequate hormone use. Several patients were informed about definitive infertility as a consequence of the antitumor treatment. In contrast
6 1002 S.I. Verschuuren et al. with this, other patients were prescribed GnRH analogs to protect the ovaries. Remarks made by the patients on the questionnaires revealed a considerably diverging approach by attending physicians. Conclusions The effect of antitumor treatment for HL on ovarian function is age dependent. In our study, this effect was proven by an odds ratio of 1.18 per year (95% CI/ ) (Figure 1). There is a striking inconsistency regarding the management of ovarian protection before and during antitumor treatment. Protocols for assessment and management of loss of ovarian function after antitumor treatment should be developed and standardized. This should be initiated in a multidisciplinary setting, in collaboration between hematologists and gynecologists. Furthermore, there is an obvious need to conduct multicenter randomized controlled trials on interventions that may prevent the loss of ovarian function after treatment. References 1. Posada MN, Kolp L, Garcia JE. Fertility options for female cancer patients: facts and fiction. Fertil Steril 2001; 75(4): Review. 2. Revel A, Laufer N. Protecting female fertility from cancer therapy. Mol Cell Endocrinol 2002; 187(12): Review. 3. Falcone T, Attaran M, Bedaiwy MA, Goldberg JM. Ovarian function preservation in the cancer patient. Fertil Steril 2004; 81(2): Review. 4. Raemaekers J, Kluin-Nelemans H, Teodorovic I, Meerwaldt C, Noordijk E, Thomas J, Glabbeke M, Henry-Amar M, Carde P. The achievements of the EORTC Lymphoma Group. European Organisation for Research and Treatment of Cancer. Eur J Cancer. 2002;/38(Suppl 4):/S Klip H, Burger CW, de Kraker J, van Leeuwen FE; OMEGAproject group. Risk of cancer in the offspring of women who underwent ovarian stimulation for IVF. Hum Reprod 2001; 16(11): Specht L, Hansen M, Geisler C. Ovarian function in young women in long term remission after treatment for Hodgkin s disease stage I and II. Scand J Haematol. 1984;/32:/ Shahin MS, Puscheck E. Reproductive sequelae of cancer treatment. Obstet Gynecol Clin North Am. 1998;/25(2): / Kreuser ED, Xiros N, Hetzel WD, Heimpel H. Reproductive and endocrine gonadal capacity in patients treated with COPP for Hodgkin s disease. J Cancer Res Clin Oncol. 1987;/113(3):/ Kreuser ED, Hetzel WD, Billia DO, Thiel E. Gonadal toxicity following cancer therapy in adults: significance, diagnosis, prevention and treatment. Cancer Treat Rev. 1990;/17(23):/ Brandt L, Kimby E, Nygren P, Glimelius B. A systemic overview of chemotherapy effects in Hodgkin s disease. Acta Oncol. 2001;/40(2/3):/ Bokemeyer C, Schmoll HJ, van Rhee J, Kuczyk M, Schuppert F, Poliwoda H. Long-term gonadal toxicity after the therapy for Hodgkin s and non-hodgkin s lymphoma. Ann Hematol. 1994;/68(3):/ Barton C, Waxman J. Effects of chemotherapy on fertility. Blood Rev. 1990;/4(3):/ Clark ST, Radford JA, Crowther D, Swindell R, Shalet SM. Gonadal function following chemotherapy for Hodgkin s disease: a comparative study of MVPP and a seven-drug hybrid regimen. J Clin Oncol. 1995;/13(1):/ Waxman JH, Ahmed R, Smith D, Wrigley PF, Gregory W, Shalet S, Crowther D, Rees LH, Besser GM, Malpas JS, et al. Failure to preserve fertility in patients with Hodgkin s disease. Cancer Chemother Pharmacol. 1987;/19:/ Pereyra Pacheco B, Mendez Ribas JM, Milone G, Fernandez I, Kvicala R, Mila T, Di Noto A, Contreras Ortiz O, Pavlovsky S. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol. 2001;/81:/ Blumenfeld Z, Eckman A. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a. J Natl Cancer Inst Monogr. 2005;/34:/ Oktay K, Buyuk E. Ovarian transplantation in humans: indications, techniques and the risk of reseeding cancer. Eur J Obstet Gynecol Reprod Biol. 2004;/113(suppl):/ Radford JA, Lieberman BA, Brison DR, Smith AR, Critchlow JD, Russell SA, Watson AJ, Clayton JA, Harris M, Gosden RG, Shalet SM. Orthotopic reimplantation of cryopreserved ovarian cortical strips after high-dose chemotherapy for Hodgkin s lymphoma. Lancet. 2001;/357(9263):/ Schmidt KL, Andersen CY, Loft A, Byskov AG, Ernst E, Andersen AN. Follow-up of ovarian function post-chemotherapy following ovarian cryopreservation and transplantation. Hum Reprod. 2005;/20(12):/ Epub 2005 Aug Donnez J, Dolmans MM, Demylle D, Jadoul P, Pirard C, Squifflet J, Martinez-Madrid B, van Langendonckt A. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004;/364(9443):/ Erratum in: Lancet 2004 Dec 4; 364(9450): Meirow D, Levron J, Eldar-Geva T, Hardan I, Fridman E, Zalel Y, Schiff E, Dor J. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med. 2005;/353(3):/ Oktay K, Buyuk E, Veeck L, Zaninovic N, Xu K, Takeuchi T, Opsahl M, Rosenwaks Z. Embryo development after heterotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004;/363(9412):/ Kim SS, Radford J, Harris M, Varley J, Rutherford AJ, Lieberman B, Shalet S, Gosden R. Ovarian tissue harvested from lymphoma patients to preserve fertility may be safe for autotransplantation. Hum Reprod. 2001;/16:/ Van Leeuwen FE, Klokman WJ, Stovall M, Dahler EC, van t Veer MB, Noordijk EM, Crommelin MA, Aleman BM, Broeks A, Gospodarowicz M, Travis LB, Russell NS. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin s disease. J Natl Cancer Inst. 2003;/95(13):/ Chapman RM, Sutcliffe SB, Malpas JS. Cytotoxic-induced ovarian failure in Hodgkin s disease. II. Effects on sexual function. JAMA. 1979;/242(17):/ Chapman RM. Effect of cytotoxic therapy on sexuality and gonadal function. Semin Oncol. 1982;/9(1):/8494.
Obstetrics, Université Libre de Bruxelles, Erasme Hospital, Brussels, Belgium
The Oncologist Prevention Fertility Preservation: Successful Transplantation of Cryopreserved Ovarian Tissue in a Young Patient Previously Treated for Hodgkin s Disease ISABELLE DEMEESTERE, a,b PHILIPPE
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Schaapveld M, Aleman BMP, van Eggermond AM, et al. Second cancer
More informationEvidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors.
Evidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors. Who needs surveillance? Chiarelli et al. Early menopause and Infertility
More information10/16/2014. Adolescents (ages 10 19) and young adults (ages 20 24) together compose about 21% of the population of the United States.
The purview of pediatrics includes the growth, development, and health of the child and therefore begins in the period before birth when conception is apparent. It continues through childhood and adolescence
More informationSpontaneous recovery of ovarian function and fertility after cancer treatment
Rigshospitalet The Fertility Clinic Copenhagen, Denmark Spontaneous recovery of ovarian function and fertility after cancer treatment Kirsten Tryde Macklon, Ph.D. 5th society of reproductive medicine and
More informationChapter 9. Yasmin Gosiengfiao, MD
Chapter 9 Progress, History and Promise of Ovarian Cryopreservation and Transplantation for Pediatric Cancer Patients T.K. Woodruff and K.A. Snyder (eds.) Oncofertility. Springer 2007 The original publication
More informationCancer and Fertility Ashley Munchel, MD Assistant Professor of Pediatrics University of Maryland Medical Center
Cancer and Fertility Ashley Munchel, MD Assistant Professor of Pediatrics University of Maryland Medical Center Trends in Pediatric Cancer Incidence Rates by Site, Ages Birth to 19 Years, 1975 to 2010.
More informationFERTILITY AND PREGNANCY AFTER BREAST CANCER LISA KOLP, MD JOHNS HOPKINS SCHOOL OF MEDICINE OCTOBER 2013
FERTILITY AND PREGNANCY AFTER BREAST CANCER LISA KOLP, MD JOHNS HOPKINS SCHOOL OF MEDICINE OCTOBER 2013 SPECIAL THANKS TO DR. MINDY CHRISTIANSON INTRODUCTION About 6-7% of breast cancers are diagnosed
More informationComparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages I-II Hodgkin s Lymphoma (HL):
Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages I-II Hodgkin s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial H. Eghbali, P.
More informationCHILDHOOD CANCER SURVIVOR STUDY ANALYSIS CONCEPT PROPOSAL
CHILDHOOD CANCER SURVIVOR STUDY ANALYSIS CONCEPT PROPOSAL STUDY TITLE: Infertility and the use of fertility treatments in female survivors of childhood cancer. WORKING GROUP Chronic Disease INVESTIGATORS:
More informationGynecologic Considerations in Women with FA
Gynecologic Considerations in Women with FA RAHEL GHEBRE, M.D., MPH University of Minnesota Medical School Objectives Recommendation for Gynecologic Care FA girls starting at age 16 should establish a
More informationTHE EORTC-GELA TREATMENT STRATEGY IN CLINICAL STAGES I-II HL Results of the H9-F and H9-U trials (#20982)
EORTC Lymphoma Group THE EORTC-GELA TREATMENT STRATEGY IN CLINICAL STAGES I-II HL Results of the H9-F and H9-U trials (#20982) J. Thomas, C. Fermé, E.M. Noordijk, H. Eghbali and M. Henry-Amar 7th International
More informationUpdated Analysis of Non-Surgical Premature Menopause in the Childhood Cancer Survivor Study
Analysis Concept Proposal 1. Study Title Updated Analysis of Non-Surgical Premature Menopause in the Childhood Cancer Survivor Study 2. Working Group and Investigators CCSS Working Group: Chronic Disease
More informationOptimizing Fertility and Wellness After Cancer. Kat Lin, MD, MSCE
Optimizing Fertility and Wellness After Cancer Kat Lin, MD, MSCE University Reproductive Care University of Washington Nov. 6, 2010 Optimism in Numbers 5-year survival rate 78% for all childhood cancers
More informationReferences 1. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, CA Cancer J Clin, (1): p Keegan, T.H., et al., Compa
1. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2018. CA Cancer J Clin, 2018. 68(1): p. 7 30. 2. Keegan, T.H., et al., Comparison of cancer survival trends in the United States of adolescents
More informationThe Adolescent: A Patient at Risk: Ovarian Failure in Adolescent Cancer Survivors
The Adolescent: A Patient at Risk: Ovarian Failure in Adolescent Cancer Survivors Avner Hershlag MD Professor and Chief Center for Human Reproduction North Shore LIJ Hofsra university School of Medicine
More informationChapter 17 Oncofertility Consortium Consensus Statement: Guidelines for Ovarian Tissue Cryopreservation
Chapter 17 Oncofertility Consortium Consensus Statement: Guidelines for Ovarian Tissue Cryopreservation Leilah E. Backhus, MD, MS, Laxmi A. Kondapalli, MD, MS, R. Jeffrey Chang, MD, Christos Coutifaris,
More informationChapter 4. Managing Fertility in Childhood Cancer Patients T.K. Woodruff and K.A. Snyder (eds.) Oncofertility. Springer 2007
Chapter 4 Managing Fertility in Childhood Cancer Patients T.K. Woodruff and K.A. Snyder (eds.) Oncofertility. Springer 2007 The original publication of this article is available at www.springerlink.com
More informationLa preservazione della fertilità in oncologia: il carcinoma mammario come paradigma. Olivia Pagani Centro di Senologia dellasvizzera Italiana
La preservazione della fertilità in oncologia: il carcinoma mammario come paradigma Olivia Pagani Centro di Senologia dellasvizzera Italiana Centro di Senologia della Svizzera Italiana Pregnancy rate after
More informationDisturbances of female reproductive system in survivors of childhood cancer
Disturbances of female reproductive system in survivors of childhood cancer Assoc. Prof. Zana Bumbuliene VU Faculty of Medicine Clinic of Obstetrics and Gynaecology 13 SEP 2014 Introduction Cancer is the
More informationRadiation therapy has a dramatic effect on lymphomas, and has played an important role in treating Hodgkin
COUNTERPOINTS Current Controversies in Hematology and Oncology Can Radiotherapy Be Omitted in Patients With Localized Hodgkin Lymphoma? Radiation therapy has a dramatic effect on lymphomas, and has played
More informationFertility effects of cancer treatment
THEME: Cancer survivors Fertility effects of cancer treatment Donald E Marsden, Neville F Hacker BACKGROUND Cancer sufferers are a subfertile group, and most treatments have the potential to adversely
More informationShould we offer fertility preservation to all patients with severe endometriosis?
Should we offer fertility preservation to all patients with severe endometriosis? Daniel S. Seidman, MD Department of Ob/Gyn, Sheba Medical Center, Sackler School of Medicine, Tel-Aviv University Endometriosis
More informationOVARIAN CRYOPRESERVATION: BACKGROUND, FERTILITY PREDICTION AND THE EDINBURGH EXPERIENCE
OVARIAN CRYOPRESERVATION: BACKGROUND, FERTILITY PREDICTION AND THE EDINBURGH EXPERIENCE Professor W Hamish Wallace Consultant Paediatric Oncologist Royal Hospital for Sick Children Edinburgh hamish.wallace@nhs.net
More informationGerman Hodgkin Study Group
German Hodgkin Study Group Deutsche Hodgkin Studiengruppe Avoiding Relapse of Hodgkin Lymphoma: Have We Moved The Needle? Andreas Engert, MD Chairman, German Hodgkin Study Group University Hospital of
More informationHum. Reprod. Advance Access published August 25, 2005
Human Reproduction Page 1 of 6 Hum. Reprod. Advance Access published August 25, 2005 doi:10.1093/humrep/dei268 Restoration of ovarian function after orthotopic (intraovarian and periovarian) transplantation
More informationLymphology 28 (1995) 73-77
73 Lymphology 28 (1995) 73-77 Lymphological Laboratory (PH), Department of Gynecology, University of Tiibingen, Germany and Fifth Department of Internal Medicine (EZ), Silesian Medical Academy, Poland
More informationFertility and fertility preservation techniques for breast cancer patients
Middle East Fertility Society Journal Vol. 12, No. 3, 2007 Copyright Middle East Fertility Society OPINION Fertility and fertility preservation techniques for breast cancer patients Fouzia Memon, M.B.B.S.
More informationOocyte Freezing and Ovarian Tissue Cryopreservation:
Oocyte Freezing and Ovarian Tissue Cryopreservation: Comparing Results of These Two Methods in One Program Dr. César Díaz García cesar.diaz@ivi.uk IVI London 83, Wimpole St. London, UK London Conflict
More informationPrimary treatment of Hodgkin s disease
DOI: 10.1093/annonc/mdf653 Primary treatment of Hodgkin s disease G. P. Canellos Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA Introduction Therapeutic research in human
More informationRETURN OF NORMAL TESTICULAR ACTIVITY IN CURED PATIENTS OF LYMPHOMA
RETURN OF NORMAL TESTICULAR ACTIVITY IN CURED PATIENTS OF LYMPHOMA Sanaullah Kuchay 1, Zahoor Ahmad Paul 2, Mushood Nabi 3 1Associate Professor and HOD, Department of Radiation Oncology, Government Medical
More informationFertility in young men and women after treatment for
J Clin Pathol 1985;38:1247-1251 Fertility in young men and women after treatment for lymphoma: a study of a population DJ KING, MA RATCLIFFE, AA DAWSON, B BENNETT, JE MACGREGOR,* AI KLOPPERt From the Departments
More information03/14/2019. GnRH Analogs for Fertility Preservation: What are the Data? Educational Objectives. Outline
GnRH Analogs for Fertility Preservation: What are the Data? AHN-JH SKCCC Current Topics in Breast Cancer Symposium Karen Lisa Smith MD MPH Assistant Professor Johns Hopkins Breast and Cancer Program March
More informationLong-term risk of second malignancy after treatment of Hodgkin s disease: the influence of treatment, age and follow-up time
Original article Annals of Oncology 13: 1786 1791, 2002 DOI: 10.1093/annonc/mdf289 Long-term risk of second malignancy after treatment of Hodgkin s disease: the influence of treatment, age and follow-up
More informationPediatric Grand Rounds - UT Health SA 09/14/2018
Fertility Preservation: Who, What, Why, When and How Glenn L. Schattman, MD Associate Professor The Center for Reproductive Medicine and Infertility Weill Medical College of Cornell University Disclosure
More informationPrevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients
Annals of Oncology 17: 74 78, 2006 doi:10.1093/annonc/mdj029 Published online 27 October 2005 Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early
More informationRESEARCH ARTICLE. Effects of Radiotherapy on the Risk of Developing Secondary Malignant Neoplasms in Hodgkin s Lymphoma Survivors
DOI:http://dx.doi.org/10.7314/APJCP.2016.17.2.749 Effects of Radiotherapy on Risk of Developing Secondary Malignant Neoplasms in Hodgkin s Lymphoma Survivors RESEARCH ARTICLE Effects of Radiotherapy on
More informationFemale Health Issues after Treatment for Childhood Cancer
Female Health Issues after Treatment for Childhood Cancer The effects of childhood cancer therapy on female reproductive function depend on many factors, including the girl s age at the time of cancer
More informationCitation for published version (APA): Aleman, B. M. P. (2007). Optimizing treatment of patients with Hodgkin's lymphoma
UvA-DARE (Digital Academic Repository) Optimizing treatment of patients with Hodgkin's lymphoma Aleman, B.M.P. Link to publication Citation for published version (APA): Aleman, B. M. P. (2007). Optimizing
More informationBreast cancer & Fertility. Do we provide good information?
Breast cancer & Fertility. Do we provide good information? M Fastrez, C Houba 27 4 13 CHU S t Pierre Réseau IRIS University of Brussels We have no conflict of interest to disclose. Summary Introduction:
More informationREPRODUCTIVE HEALTH IN YOUNG ADULT CANCER SURVIVORS
REPRODUCTIVE HEALTH IN YOUNG ADULT CANCER SURVIVORS Laxmi A Kondapalli, MD MSCE Colorado Center for Reproductive Medicine Disclosure The speaker has no financial or other conflict of interest Objectives
More informationFERTILITY PRESERVATION. Juergen Eisermann, M.D., F.A.C.O.G South Florida Institute for Reproductive Medicine South Miami Florida
FERTILITY PRESERVATION Juergen Eisermann, M.D., F.A.C.O.G South Florida Institute for Reproductive Medicine South Miami Florida 1 2 3 4 Oocyte Cryopreservation Experimental option Offer to single cancer
More informationHodgkin Lymphoma Status of the art of treatment
11.05.2016 1 Hodgkin Lymphoma Status of the art of treatment Peter Borchmann German Hodgkin Study Group University of Cologne, Germany Question No 1: Which statement regarding 1 st line treatment of early
More informationA nationwide survey of oncologists regarding treatment-related infertility and fertility preservation in female cancer patients
A nationwide survey of oncologists regarding treatment-related infertility and fertility preservation in female cancer patients Eric J. Forman, M.D., a Carey K. Anders, M.D., b and Millie A. Behera, M.D.
More informationT.K. Woodruff et al. (eds.), Oncofertility, Cancer Treatment and Research 156, 3 DOI / _1.
Chapter 1 Reproductive Health After Cancer Clarisa R. Gracia C.R. Gracia (B) Department of Reproductive Endocrinology and Infertility, University of Pennsylvania, Philadelphia, PA, USA e-mail: cgracia@obgyn.upenn.edu
More informationMelanoma-What Every Woman Need to Know about Fertility and Pregnancy
Melanoma-What Every Woman Need to Know about Fertility and Pregnancy Women diagnosed with melanoma may require counseling for fertility preservation, fertility treatment and safety of pregnancy after treatment.
More informationFertility preservation in the (young) cancer patient
Fertility preservation in the (young) cancer patient Professor W Hamish B Wallace University of Edinburgh & Royal Hospital for Sick Children, Edinburgh, Scotland, UK hamish.wallace@nhs.net ESMO Madrid
More informationRT in Hodgkin Lymphoma
RT in Hodgkin Lymphoma Lesser is better? Philip Poortmans, M.D. Ph.D. Radiation oncologist Tilburg, The Netherlands Radiation dose in Hodgkin Lymphoma Introduction Current evidence Guidelines 1.0 Early
More informationPEDIATRIC & ADOLESCENT CANCER SURVIVORSHIP. Denise Rokitka, MD, MPH
PEDIATRIC & ADOLESCENT CANCER SURVIVORSHIP Denise Rokitka, MD, MPH Objectives Describe incidence of childhood cancer and survival rates and causes of early mortality. Understand the late effects of cancer
More informationOVARIAN FUNCTION AFTER CHILDHOOD CANCER
OVARIAN FUNCTION AFTER CHILDHOOD CANCER Practicing through Controversy Diane Puccetti MD Leslie Coker Appiah MD NASPAG April 2018 Objectives Review use and limitations of risk stratification. Understand
More informationSARCOMA/GIST AND FERTILITY
SARCOMA/GIST AND FERTILITY Christine Rousset-Jablonski Medical Gynecologist Léon Bérard Cancer Center, Lyon SPAEN conference, Milan 2018 Fertility/ Pregnancy after cancer A major concern for patients surviving
More informationImpact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers
Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers Andrea Reh, M.D., Ozgur Oktem, M.D., and Kutluk Oktay, M.D.
More informationProject: Reduction of risk of long-term complications of radiotherapy for lymphomas.
Project: Reduction of risk of long-term complications of radiotherapy for lymphomas. PI: Lena Specht, Rigshospitalet, University of Copenhagen Other participants: Ivan Vogelius, physicist, Rigshospitalet,
More informationReproductive function in cancer survivors
Reproductive function in cancer survivors Professor W Hamish Wallace hamish.wallace@nhs.net Symposium 20: Endocrine consequences of childhood cancer treatment Liffey Hall 2, 0905 19 May 2015 CONFLICT OF
More informationReproductive outcome after transplantation of ovarian tissue: a systematic review
Human Reproduction Vol.23, No.12 pp. 2709 2717, 2008 Advance Access publication on August 9, 2008 doi:10.1093/humrep/den301 Reproductive outcome after transplantation of ovarian tissue: a systematic review
More informationOncofertility: An Emerging Discipline in Obstetrics and Gynecology
23 CME REVIEWARTICLE Volume 68, Number 8 OBSTETRICAL AND GYNECOLOGICAL SURVEY Copyright * 2013 by Lippincott Williams & Wilkins CHIEF EDITOR S NOTE: This article is part of a series of continuing education
More informationFERTILITY PRESERVATION OPTIONS FOR CANCER PATIENTS
FERTILITY PRESERVATION OPTIONS FOR CANCER PATIENTS Justo Callejo Olmos, 1 Laura Almeida Toledano 2 1. Professor and Clinical Chief of Gynecology, Department of Obstetrics and Gynaecology, Hospital Sant
More informationNational Physicians Cooperative of the Oncofertility Consortium
National Physicians Cooperative of the Oncofertility Consortium Section 10. Ovarian Tissue Freezing, Thawing, Labeling, and Testing Date Adopted Supersedes Procedure # 11/1/2010 12/15/2009; 11/1/2009;
More informationEvolving Approaches to Primary Treatment of Hodgkin Lymphoma
Evolving Approaches to Primary Treatment of Hodgkin Lymphoma Joseph M. Connors Two challenges confront the clinician treating Hodgkin lymphoma today: achieving a high level of effectiveness while minimizing
More informationCHEMOTHERAPY. Chemo, Ctx, Ctx. A category of cancer treatment that uses one or more anti-cancer drugs. Risk factor Male & Female
CHEMOTHERAPY Chemo, Ctx, Ctx A category of cancer treatment that uses one or more anti-cancer drugs. Risk factor Male & Female About Chemotherapy Chemotherapy is a category of cancer treatment that uses
More informationA multi-centre, multinational, cross-sectional, incident case control study on Factors associated with the development of
A multi-centre, multinational, cross-sectional, incident case control study on Factors associated with the development of Endometrioma and deep infiltrating endometriosis Professor C. Chapron and the Group
More informationLimited-Stage Disease: Optimal Use of Chemotherapy and Radiation Treatment
HODGKIN LYMPHOMA: CLINICAL CHALLENGES Limited-Stage Disease: Optimal Use of Chemotherapy and Radiation Treatment John Radford 1 1 Professor of Medical Oncology, Christie Hospital and The University of
More informationFemale Health Issues after Treatment for Childhood Cancer
after Treatment for Childhood Cancer The effects of childhood cancer therapy on female reproductive function depend on many factors, including the girl s age at the time of cancer therapy, the specific
More informationMedical Late Effects of Childhood Cancer
Medical Late Effects of Childhood Cancer Robert Goldsby Associate Professor of Clinical Pediatric UCSF Late Mortality in 5+ Year Survivors 1.00 US Female US Male Survival function estimate 0.70 0.75 0.80
More informationFertility care for women diagnosed with cancer
Saint Mary s Hospital Department of Reproductive Medicine Information for Patients Fertility care for women diagnosed with cancer Contents Page Overview... 2 Our service... 2 Effects of cancer treatment
More informationCancer and fertility preservation: international recommendations from an expert meeting
Lambertini et al. BMC Medicine (2016) 14:1 DOI 10.1186/s12916-015-0545-7 CORRESPONDENCE Cancer and fertility preservation: international recommendations from an expert meeting Open Access Matteo Lambertini
More informationUse of Ovarian Suppression and Ablation in Breast Cancer Treatment
Use of Ovarian Suppression and Ablation in Breast Cancer Treatment Dr Marina Parton Consultant Medical Oncologist Royal Marsden and Kingston Hospitals Overview Breast cancer phenotypes Use of ovarian manipulation
More informationAnalysis of post-warming degeneration & apoptosis following porcine ovarian tissue vitrification using the ohio-cryo device
Analysis of post-warming degeneration & apoptosis following porcine ovarian tissue vitrification using the ohio-cryo device e-poster: 363 Congress: ESHRE 2008 Type: Scientific poster Topic: ART, laboratory:
More informationAge Related fertility Preservation: Should you Consider Multiple Egg Freezing Cycles?
Age Related Fertility Preservation: Should you Consider Multiple Egg Freezing Cycles? Age Related fertility Preservation: Should you Consider Multiple Egg Freezing Cycles? All what we really know for sure
More informationCancer after ART. A Dutch nationwide historic cohort of women who received IVF treatment in the
1 Cancer after ART Curt Burger, The Netherlands A Dutch nationwide historic cohort of 19.158 women who received IVF treatment in the Netherlands between 1983 and 1995, and a comparison group of 5.950 subfertile
More informationGONADAL, ADRENAL, ANDROGEN AND THYROID FUNCTIONS IN ADULTS TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA
original paper Haematologica 1994; 79:141-147 GONADAL, ADRENAL, ANDROGEN AND THYROID FUNCTIONS IN ADULTS TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA Fiorina Giona*, Luciana Annino*, Paola Donato, Michele
More informationLate effects after treatment for malignant lymphoma. Cecilie Essholt Kiserud, MD
Late effects after treatment for malignant lymphoma Cecilie Essholt Kiserud, MD Department of Clinical Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Faculty of Medicine, University
More informationCancer Fertility. Fertility Options to Consider Before Treatment Begins & Parenthood Options After Cancer
& Cancer Fertility Fertility Options to Consider Before Treatment Begins & Parenthood Options After Cancer If you or someone you care about is faced with a cancer diagnosis, preserving fertility may be
More informationFertility in cancer patients after cryopreservation of one ovary
Reproductive BioMedicine Online (2013) 26, 272 279 www.sciencedirect.com www.rbmonline.com ARTICLE Fertility in cancer patients after cryopreservation of one ovary KT Schmidt a,b, *, A Nyboe Andersen a,
More informationPlanning for Parenthood After a Cancer Diagnosis
Cancer and Fertility Planning for Parenthood After a Cancer Diagnosis If you or someone you love is facing cancer, preserving fertility may be the last thing on your mind. But if you re a woman of childbearing
More informationReview Article Cancer, Fertility Preservation, and Future Pregnancy: AComprehensiveReview
Obstetrics and Gynecology International Volume 2012, Article ID 953937, 11 pages doi:10.1155/2012/953937 Review Article Cancer, Fertility Preservation, and Future Pregnancy: AComprehensiveReview Michelle
More informationLong Term Toxicity of Endocrine Therapy for premenopausal women with ER positive breast cancer
Global Breast Cancer Conference 2017 21 st Apr, 2017@Chezu Island Long Term Toxicity of Endocrine Therapy for premenopausal women with ER positive breast cancer Shinji Ohno, M.D., Ph.D., F.A.C.S. Breast
More informationFertility Preservation. Anne Katz PhD RN FAAN
Fertility Preservation Anne Katz PhD RN FAAN Why is fertility preservation important to YAs after cancer? Normality (Crawshaw & Sloper, 2010) Preference for biologic offspring vs. adoption (Schover 2002)
More informationOvarian age-based stimulation of young women with diminished ovarian reserve results in excellent pregnancy rates with in vitro fertilization
Ovarian age-based stimulation of young women with diminished ovarian reserve results in excellent pregnancy rates with in vitro fertilization Norbert Gleicher, M.D., and David Barad, M.D. Center for Human
More informationONKOFERTILITETNI POSTUPCI NAŠA ISKUSTVA. Vrtačnik Bokal Eda
ONKOFERTILITETNI POSTUPCI NAŠA ISKUSTVA Vrtačnik Bokal Eda a trend toward delaying childbearing IN RECENT DECADES propor?on of first-?me mother > 30 years in USA (1990-2002, 4.1% to 21.2 %) as a consequence,
More informationGuideline for Fertility Preservation for Patients with Cancer
Guideline for Fertility Preservation for Patients with Cancer COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For Informational Purposes
More informationPremature Menopause : Diagnosis and Management
Guideline Number 3 : August 2010 Premature Menopause : Diagnosis and Management Introduction : Premature menopause is a serious condition that affects young women and remains an enigma. The challenges
More informationReproductive Options for Breast Cancer Patients
08:36 1 Reproductive Options for Breast Cancer Patients Mr Stuart Lavery Director IVF Hammersmith Consultant Gynaecologist Imperial College London 08:36 2 Reproductive Options for Female Cancer Patients
More informationa nonprofit organization Cancer & Fertility Fast Facts for Ob/Gyns information support hope
a nonprofit organization Cancer & Fertility Fast Facts for Ob/Gyns information support hope table of contents introduction introduction 1 role of the obstetrician-gynecologist cancer screening and diagnosis
More informationESMO Breast Cancer Preceptorship Singapore November Special Issues in Treatment of Young Women with Breast Cancer
ESMO Breast Cancer Preceptorship Singapore November 2017 Special Issues in Treatment of Young Women with Breast Cancer Prudence Francis MD Peter MacCallum Cancer Centre Melbourne, Australia Conflict of
More informationFertility preservation and pregnancy outcome after malignancy Tommaso Falcone a and Mohamed A. Bedaiwy b
Fertility preservation and pregnancy outcome after malignancy Tommaso Falcone a and Mohamed A. Bedaiwy b Purpose of review The overall survival and cure rates of patients with childhood and adult malignancies
More informationENDOMETRIOSIS PATIENTS: OOCYTE QUALITY AND QUANTITY. Grants for research received during the. last three years from Ferring and Merck-Serono
OOCYTE FREEZINGIN ENDOMETRIOSIS PATIENTS: OOCYTE QUALITY AND QUANTITY Edgardo Somigliana, MD-PhD CONFLICTS OF INTERESTS v COIs with Industry Personal: Institutional : None Grants for research received
More informationIAEA Pediatric Radiation Oncology Training Dr Laskar Version 1 June 2009 RADIATION THERAPY FOR PEDIATRIC HODGKIN S DISEASE
RADIATION THERAPY FOR PEDIATRIC HODGKIN S DISEASE THOMAS HODGKIN 1832 On Some Morbid Appearances of the Absorbent Glands & Spleen GLOBAL INCIDENCE Region Cases per 100,000 children United States 0.5 European
More informationPreservazione della fertilità nella paziente oncologica
Preservazione della fertilità nella paziente oncologica Dott.ssa Raffaella Fabbri Unità Operativa Ginecologia e Fisiopatologia della Riproduzione Umana Università degli Studi di Bologna Policlinico S.
More informationFertility Preservation for Cancer Patients
Fertility Preservation for Cancer Patients Molly Moravek, MD, MPH Director, Fertility Preservation Program Assistant Professor Reproductive Endocrinology & Infertility Department of Obstetrics & Gynecology
More informationJMSCR Vol 06 Issue 09 Page September 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i9.53 Role of Anti-Mullerian Hormone
More informationWOMEN S HEALTH SERVICES
WOMEN S HEALTH SERVICES Committed to enhancing the total well-being of women throughout their lives Knowledge-Powered Medicine 877-WSU-DOCS upgdocs.org/womenshealth WOMEN S HEALTH SERVICES UPG Women s
More informationValidity of Self-reported Causes of Subfertility
American Journal of Epidemiology Copyright ª 2005 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 161, No. 10 Printed in U.S.A. DOI: 10.1093/aje/kwi120 Validity of Self-reported
More informationUse of in vitro maturation for fertility preservation
Use of in vitro maturation for fertility preservation G. Arroyo Servei de Medicina de la Reproducció Departament d Obstetrícia, Ginecologia i Reproducció INSTITUT UNIVERSITARI DEXEUS MEDICAL STRATEGY TO
More informationOvarian function and pregnancy after Hematopoietic Stem Cell Transplant
Ovarian function and pregnancy after Hematopoietic Stem Cell Transplant Factors that influence post transplantation fertility and ovarian function in women Total body irradiation (TBI) Drugs prescribed
More informationLong term cancer risks in women after treatment with in vitro fertilization: do we have any answers yet?
This is the author's version of: Stewart, L. and Hart, R. 2015. Editorial: Long-term cancer risks in women after treatment with IVF: do we have any answers yet? Women's Health. 11 (1): pp. 7-10. doi: http://doi.org/10.2217/whe.14.58
More informationRelapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage
More informationMale Sexual Function After Autologous Blood or Marrow Transplantation
Biology of Blood and Marrow Transplantation 7:279-283 (2001) 2001 American Society for Blood and Marrow Transplantation ASBMT Male Sexual Function After Autologous Blood or Marrow Transplantation Aaron
More informationLOW RESPONDERS. Poor Ovarian Response, Por
LOW RESPONDERS Poor Ovarian Response, Por Patients with a low number of retrieved oocytes despite adequate ovarian stimulation during fertility treatment. Diagnosis Female About Low responders In patients
More information